ScienceON 검색
ScienceON '특허' 검색
더보기| No | 제목 / 내용 |
|---|---|
| 1 |
ANTI C-MET ANTIBODY AND USES THEREOF / SAMSUNG ELECTRONICS CO LTD An anti c-Met antibody or antibody fragment and pharmaceutical composition comprising same, as well as a method for preventing and treating cancer by administering the antibody to a subject. |
| 2 |
ANTI C-MET ANTIBODY AND USES THEREOF / SAMSUNG ELECTRONICS CO LTD An anti c-Met antibody or antibody fragment and pharmaceutical composition comprising same, as well as a method for preventing and treating cancer by administering the antibody to a subject. |
| 3 |
ANTI-C-MET ANTIBODY AND USES THEREOF / LEE, Seung Hyun An anti-c-Met antibody or antibody fragment and pharmaceutical composition comprising same, as well as a method for preventing and treating cancer by administering the antibody to a subject are provided. |
| 4 |
ANTI C-MET ANTIBODY AND USES THEREOF / Samsung Electronics Co., Ltd. An anti-c-Met antibody or antibody fragment and pharmaceutical composition comprising same, as well as a method for preventing and treating cancer by administering the antibody to a subject are provided. |
| 5 |
METHOD OF COMBINATION THERAPY USING AN ANTI-C-MET ANTIBODY / Samsung Electronics Co., Ltd. A method for prevention or treatment of a cancer, comprising co-administering (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib or a combination thereof, to a subject in need thereof, and a pharmaceutical composition comprising (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib, or a combination thereof are provided. |
| 6 |
Method of combination therapy using an anti-C-Met antibody / SAMSUNG ELECTRONICS CO., LTD. A method for prevention or treatment of a cancer, comprising co-administering (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib or a combination thereof, to a subject in need thereof, and a pharmaceutical composition comprising (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib, or a combination thereof are provided. |
ScienceON '논문' 검색
더보기| No | 제목 / 내용 |
|---|
ScienceON '보고서' 검색
더보기| No | 제목 / 내용 |
|---|